Longevity Science with Matt Kaeberlein

About Longevity Science with Matt Kaeberlein

What does the science really say about living longer and staying healthier as we age? On Longevity Science, Matt Kaeberlein—professor, entrepreneur, and longtime leader in the field— explores the biology underlying human and animal healthspan and the interventions that might actually make a difference. From rapamycin and peptides to lifestyle, diagnostics, and emerging therapies like epigenetic reprogramming, this podcast separates signal from noise in a space often dominated by hype. No shortcuts. No miracle cures. Just thoughtful conversations grounded in real science.

Publisher

Matt Kaeberlein

Category

health & fitness

Language

en

Explicit

No

First episode

19 May 2026

Latest episode

6 Oct 2026

Latest episodes

32 episodes in the feed.

1. 

   6 Oct 2026

   Peptides, Astronauts, and AI: Lessons from the First 10,000 Longevity Experiments at Ora Biomedical

   What can we learn from the first 10,000 experiments in the search for interventions that extend healthy lifespan?In this episode of Longevity Science, I sit down with Dr. Ben Blue, CEO of Ora Biomedical, and Dr. Blair Zhao, CSO, for an update on Ora’s effort to systematically screen interventions for effects on lifespan and healthspan.We start with the Million Molecule Challenge and some intriguing new results from a screen of roughly 300 peptides, including known peptides, AI-predicted candidates, and structurally diverse molecules. We discuss what Ora is beginning to learn from nearly 10,000 intervention experiments, why existing datasets may not be sufficient to predict longevity therapeutics with AI, and how large-scale experimental data could eventually change that. We also explore an unexpected direction emerging from these experiments: resilience. Rather than asking only whether a molecule extends lifespan, can longevity interventions improve the body's ability to recover from damage? That question has led Ora from lifespan studies in C. elegans to UV and radiation resistance, human skin cells, animal studies, and potential applications ranging from photoaging and cancer radiation therapy to protecting pilots and astronauts from radiation exposure. Along the way, Ben and Blair share early results from Ora’s pipeline, including a longevity-associated compound that reduced radiation dermatitis burden by approximately 40% in a mouse model, as well as work on natural products that may improve recovery from UV damage. We also discuss the challenge of translating discoveries from worms into humans and whether resilience could provide a practical path for testing longevity therapeutics on a much shorter timescale. Disclosure: I am a co-founder of Ora Biomedical and serve on its Board of Directors. I have a financial interest in the company. This relationship is disclosed so viewers can appropriately consider this potential conflict of interest when evaluating the discussion.Topics include: the Million Molecule Challenge, AI and longevity drug discovery, peptide therapeutics, C. elegans, mTOR, stress resilience, UV damage, radiation therapy, skin aging, natural products, astronauts and spaceflight, and translating longevity interventions to humans.DISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.More places to find me:Instagram: https://www.instagram.com/mkaeberlein/LinkedIn: https://www.linkedin.com/in/mkaeberlein/Twitter: https://twitter.com/mkaeberleinFacebook: https://www.facebook.com/matt.kaeberlein/

2. 

   25 Sept 2026

   Longevity Roundtable: GLP-1s, Statins, Aging Clocks & Right to Try

   In this episode of Longevity Roundtable for September 2026, I’m joined by Brian Kennedy and Marcus Ranney to dig into some of the biggest recent stories in longevity science and medicine.We start with Marcus fresh off a high-altitude marathon and discuss intermittent hypoxia, hyperoxia, and hyperbaric oxygen therapy. From there, we take a close look at the new mouse lifespan data on semaglutide and what it does, and doesn’t, tell us about GLP-1 drugs and biological aging. We also discuss concerns about GLP-1s and vision loss, and how to think about potential risks in the context of their demonstrated benefits.Then we turn to new evidence linking statin use with reduced dementia risk, the persistent concern that lowering cholesterol could negatively affect the brain, and what the evidence actually suggests.We also tackle a recent Nature Medicine study asking whether epigenetic aging clocks respond to longevity interventions. Can these clocks really tell us whether an intervention is slowing biological aging? And what should we make of the fact that interventions like exercise and rapamycin don't necessarily move them in the direction we might expect?Finally, we discuss Montana’s new Right to Try framework for experimental therapies, why I agreed to serve on its review board, and whether new regulatory models could generate useful clinical data while giving patients greater access to experimental treatments. And, naturally, we finish with Bryan Johnson—because apparently no Longevity Roundtable is complete without him.Topics include: GLP-1 agonists and lifespan, semaglutide, intermittent hypoxia, hyperbaric oxygen, statins and dementia, cholesterol and brain health, epigenetic aging clocks, rapamycin, Right to Try, experimental medicine, and the future of longevity science.DISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.More places to find me:Instagram: https://www.instagram.com/mkaeberlein/LinkedIn: https://www.linkedin.com/in/mkaeberlein/Twitter: https://twitter.com/mkaeberleinFacebook: https://www.facebook.com/matt.kaeberlein/

3. 

   18 Sept 2026

   Building a Resilient Brain with Dr. Tommy Wood

   What can we actually do to protect our brains as we age, and how much of cognitive decline may be preventable or even reversible?In this episode of Longevity Science, I sit down with neuroscientist and physician Dr. Tommy Wood, author of The Stimulated Mind, for a wide-ranging conversation about the science of brain health, cognitive resilience, and dementia risk. Tommy introduces his “3S” framework—stimulus, support, and supply—for thinking about what the brain needs to maintain and improve function across the lifespan.We discuss why brain fog and subjective cognitive decline shouldn't simply be dismissed as normal aging; the roles of cognitive stimulation, exercise, sleep, stress, metabolic and cardiovascular health; and what the evidence actually says about supplements including creatine, magnesium, omega-3s, vitamin D, multivitamins, and lithium. We also dig into pharmaceuticals and emerging approaches, including statins and PCSK9 inhibitors, GLP-1 agonists, PDE5 inhibitors, TMS and other forms of brain stimulation, and psychedelics such as psilocybin.Perhaps most importantly, we talk about reasons for optimism. Age-specific dementia incidence has declined over recent decades, and we already know much more about maintaining cognitive function than many people realize. The challenge now is figuring out how to combine what we know into strategies that help people build a more resilient brain—and maintain it for life.Topics include: brain fog and cognitive decline, dementia prevention, neuroplasticity, sleep and stress, exercise, cardiovascular and metabolic health, supplements for brain health, creatine, lithium, GLP-1 drugs, brain stimulation, psychedelics, and the future of dementia treatment.DISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.More places to find me:Instagram: https://www.instagram.com/mkaeberlein/LinkedIn: https://www.linkedin.com/in/mkaeberlein/Twitter: https://twitter.com/mkaeberleinFacebook: https://www.facebook.com/matt.kaeberlein/

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Spotify

4.6 / 5

9 ratings

Contact Longevity Science with Matt Kaeberlein

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.